Merrill keeps Vertex neutral

Vertex Pharmaceuticals Inc. was maintained at neutral by Merrill Lynch after the company reported a loss of $0.44 per share, versus the Merrill estimate of $0.34, and revenues of $36 million, $6 million less than Merrill's estimate. Analyst Hari Sambasivam upped the estimated 2005 loss per share to $1.73 from $1.64 and said Merrill will further review the outlook after the release of clinical data for Vertex's VX-950. Shares of the Cambridge, Mass.-based biotechnology company were down $0.14, or 0.62%, at $22.26 on volume of 1,161,500 shares versus the three-month running average of 1,484,640 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.